Core Insights - The article highlights a significant case where a shareholder of BGI Genomics, Mr. Han, credits the company's health screening service with saving his life by detecting early-stage cancer through a free genetic test [2][8]. Group 1: Company Initiatives - BGI Genomics launched the "2025 Annual Shareholder Return Activity," allowing long-term shareholders to receive free health screenings, which reflects the company's commitment to shareholder welfare and health [3][8]. - The company emphasizes its mission of "genetic technology benefiting humanity," aiming to improve public health and quality of life through the application of life sciences [9]. Group 2: Health Screening Impact - Mr. Han's experience illustrates the effectiveness of BGI's fecal DNA methylation testing, which can detect early signs of colorectal cancer, highlighting the importance of early screening in preventing severe health issues [10][12]. - The article notes that colorectal cancer is the second most common cancer in China, with a rising incidence among younger populations, underscoring the need for increased awareness and screening [10][12]. Group 3: Industry Context - The article discusses the challenges in colorectal cancer screening, including the low screening rates due to the invasive nature of traditional methods, and advocates for non-invasive tests like BGI's as a viable alternative [12]. - It emphasizes the importance of proactive health management, encouraging individuals to take charge of their health rather than waiting for symptoms to appear [12].